1. Finland Stocks

  2. •

    Electronic technology

  3. •

    Electronic components
Optomed Oyj Class A

Optomed Oyj Class A

HHEL:OPTOMED
1.39
EUR
-0.02
(-1.28%)
-0.27EPS
37.93MMarket Cap
Nov 06Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.5
0.52
0.97
1.68
0.98
1.1
1
0.9
0.81
0.86
0.8
Basic EPS, GAAP
- -
-0.21
-0.22
-0.1
-0.32
-0.24
-0.32
-0.37
-0.27
-0.29
-0.34
-0.27
Free Cash Flow per Basic Share
- -
-0.21
-0.2
-0.13
-0.14
-0.35
-0.41
-0.22
-0.05
-0.1
-0.15
-0.18
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.28
0.27
0.09
0.42
1.72
1.51
1.26
1.26
1.15
1.2
1.12
1.01
Tangible Book Value per Share
0.05
-0.04
-0.29
-0.55
0.76
0.55
0.3
0.46
0.37
0.49
0.46
0.36
Basic Weighted Avg Shares
13
13
13
13
9
13
13
15
17
19
20
20
Sales/Revenue/Turnover
- -
7
7
13
15
13
15
15
15
15
17
16
Operating Margin (%)
- -
-39.82
-40.99
-3.14
-17.34
-19.3
-29.44
-34.77
-26.31
-39.61
-35.34
-35.17
Depreciation Expense
- -
1
1
2
2
2
3
3
2
2
3
3
Net Income, GAAP
- -
-3
-3
-1
-3
-3
-4
-5
-4
-5
-7
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-41.73
-41.85
-10.42
-19.2
-24.42
-28.61
-37.33
-29.41
-36.24
-38.84
-33.87
Working Capital
4
2
1
-4
18
13
9
11
8
10
9
7
LT Debt
3
3
5
4
9
7
7
5
3
2
1
1
Total Equity
4
4
1
6
23
20
17
20
20
24
24
22
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-75.86
-123.22
-39.52
-20.4
-14.88
-22.89
-29.27
-21.82
-24.77
-27.87
-25.44

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
1
1
LT Borrowings
- -
1
1
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
81
49
38

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
16
14
12
Cash, Cash Equivalents & STI
10
8
7
Accounts Receivable, Net
3
3
3
Inventories
2
3
3
Total Current Liabilities
7
6
5
Payables & Accruals
- -
- -
- -
ST Debt
2
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
62.29%
4.41%
1.61%
Free Cash Flow
- -
18.27%
62.64%
Net Income, GAAP
- -
17.65%
21.83%
Sales/Revenue/Turnover
- -
5.82%
13.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
4
3
5
15
2025
4
4
4
5
17
2026
3
4
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.1
-0.09
-0.05
-0.29
2025
-0.08
-0.08
-0.08
-0.1
-0.34
2026
-0.05
-0.05
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Juho-Pekka Himberg
Full Time Employees
111
Sector
Electronic technology
Industry
Electronic components
Address
Yrttipellontie 1 Oulu NO Finland 90230
IPO Date
Dec 9, 2019
Website
optomed.com
Similar Companies
Corning Incorporated (NYSE:GLW)
Taiyo Yuden Co., Ltd. (TSE:6976)
Celestica, Inc. (NYSE:CLS)
Amphenol Corporation (NYSE:APH)
IBIDEN CO., LTD. (TSE:4062)
Vicor Corporation (NASDAQ:VICR)
Business
Optomed Oyj is a Finnish medical technology company that develops, manufactures and markets handheld fundus cameras and related software solutions for eye disease screening including diabetic retinopathy, glaucoma and age-related macular degeneration; its Devices segment offers AI-powered products such as Optomed Aurora with AEYE AI diagnostic capabilities, Optomed Smartscope PRO, the recently launched next-generation Optomed Lumo fundus camera which received FDA Class II classification enabling standalone retinal imaging without lengthy clearance and OEM-customized cameras, while the Software segment provides screening software like Cancer Screen for process management, Optomed RIS for healthcare imaging, Sectra PACS modular systems, Optomed Service Portal support functions, Cephalometry for orthodontics and oral surgery, and Pathology PACS for digital pathology image review along with IT consulting services for government institutions. Founded in 2004 and headquartered in Oulu, Finland at Yrttipellontie 1, the company operates globally across more than 60 countries through direct sales, OEM partnerships and distributors targeting hospitals, eye clinics, optician chains, primary care professionals including ophthalmologists, pediatricians, endocrinologists and neurologists, with manufacturing in Thailand and primary markets in Finland, Europe, the United States and rest of world. Recent developments include the Q2 2025 commercial launch of Optomed Lumo driving Devices segment revenue growth of 183.6% in Q3 2025 and 88.8% year-to-date, partnership expansion with a top-10 global pharmaceutical company advancing toward commercialization of a jointly developed AI algorithm for undisclosed disease detection on handheld devices, replacement of joint venture partner in China from Zhongbao Fund to WISER Management Consulting in Q2 2025 to leverage regulatory expertise and enable recurring per-patient screening revenue model where Optomed holds 19.9% ownership, strong US sales momentum for Aurora AEYE as the only handheld camera with FDA-cleared diagnostic AI absent direct competition, initiation of company-wide cost reduction and streamlining program for 2026 implementation to enhance efficiency, and reaffirmed outlook for strong full-year 2025 revenue growth over 2024 supported by mid-sized capex orders and Lumo ramp-up.